Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
The high-risk, high-reward nature of the Russell 2000 makes stock selection critical, and we’re here to guide you toward the right ones. Keeping that in mind, here are three Russell 2000 stocks to steer clear of and some alternatives to watch instead.
Artivion (AORT)
Market Cap: $1.25 billion
Formerly known as CryoLife until its 2022 rebranding, Artivion (NYSE:AORT) develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease.
Why Are We Hesitant About AORT?
- Modest revenue base of $471.5 million gives it less fixed cost leverage and fewer distribution channels than larger companies
- Cash-burning history makes us doubt the long-term viability of its business model
- ROIC of 2.4% reflects management’s challenges in identifying attractive investment opportunities
Artivion is trading at $25.62 per share, or 48.8x forward P/E. Read our free research report to see why you should think twice about including AORT in your portfolio.
BKV (BKV)
Market Cap: $2.87 billion
Operating a "closed-loop" model linking gas production to carbon capture, BKV (NYSE:BKV) produces natural gas from shale formations in Texas and Pennsylvania, selling it to utilities, industrial users, and exporters.
Why Are We Bearish on BKV?
- Subscale operations are evident in its revenue base of $1.51 billion, meaning it has fewer distribution channels than its larger rivals
- Day-to-day expenses have swelled relative to revenue over the last five years as its EBITDA margin fell by 18.8 percentage points
- Poor free cash flow margin of 0.6% for the last five years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends
BKV’s stock price of $26.28 implies a valuation ratio of 18.8x forward P/E. To fully understand why you should be careful with BKV, check out our full research report (it’s free).
Green Plains (GPRE)
Market Cap: $1.05 billion
Operating one of North America's largest ethanol platforms with capacity to process 310 million bushels of corn annually, Green Plains (NASDAQ:GPRE) operates ten biorefineries that convert corn into ethanol for fuel, distillers grains for animal feed, and renewable corn oil.
Why Are We Out on GPRE?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 3.5% annually over the last five years
- High extraction costs and unfavorable asset economics are reflected in its low gross margin of 5.8%
- Cash burn makes us question whether it can achieve sustainable long-term growth
At $14.91 per share, Green Plains trades at 9.2x forward P/E. Read our free research report to see why you should think twice about including GPRE in your portfolio.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.